2022 ESMO大会即将于9月9日（欧洲中部夏令时间，CEST）在法国首都巴黎凡尔赛门展览馆开幕。
日前，含LBA在内的大会日程安排均已公布，「肿瘤资讯」整理了会上将进行报告的肺癌研究，供参考。
Proffered Paper session & Presidential Symposium（按会议时间排序）
LBA37：一项随机、多中心2期研究(NEOpredict-Lung)：可切除NSCLC患者中进行术前纳武利尤单抗单药或联合Relatlimab（LAG-3抑制剂）治疗
原标题： A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)
报告专家：Martin H. Schuler (Essen, Germany)
LBA1：空气污染诱导的NSCLC的作用机制和可操作的炎症轴：走向分子癌症预防
原标题：Mechanism of Action and an Actionable Inflammatory Axis for Air Pollution Induced Non-Small Cell Lung Cancer: Towards Molecular Cancer Prevention
报告专家：Charles Swanton (London, United Kingdom)
LBA47：ADAURA更新，奥希替尼在可切除、IB-IIIA EGFR突变NSCLC中的新辅助治疗结局
原标题：Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC): updated results from ADAURA
报告专家：Masahiro Tsuboi (Kashiwa, Japan)
LBA48：基于社区的低剂量 CT 肺癌普查
原标题：Community-based Mass Screening with Low-Dose CT for Lung Cancer in Guangzhou
报告专家：梁文华教授（广州，中国）
950O ：O+Y联合放化疗后进行手术，在可切除、临界可切除肺癌中的结果：INCREASE试验
原标题：Ipilimumab plus Nivolumab and ChemoRadiotherapy followed by Surgery in patients with resectable and borderline resectable lung cancer: the INCREASE trial.
报告专家：Idris Bahce (Amsterdam, Netherlands)
LBA49：CANOPY-A：canakinumab(CAN) 作为完全切除NSCLC辅助治疗的 III 期研究
原标题：CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
报告专家：Edward B. Garon (Santa Monica, United States of America)
1696O：肺癌脑转移的基因组分析和分子靶向分析
原标题：Genomic profiling and molecular targeting of lung cancer brain metastases
报告专家：Haiying Cheng (Bronx, United States of America)
LBA51：基于血浆 T790M 监测的EGFR 突变NSCLC奥希替尼治疗：EORTC lung cancer Group 1613 APPLE II期随机临床试验
原标题：Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
报告专家：Jordi Remon Masip (Barcelona, Spain)
LBA52：INSIGHT 2研究初步结果，Tepotinib联合奥希替尼一线治疗奥希替尼进展后的MET扩增EGFR突变NSCLC
原标题：Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study
报告专家：Julien Mazieres (Toulouse, France)
LBA53: ELIOS，一项EGFR突变晚期NSCLC一线奥希替尼治疗的多中心分子特征研究
原标题：ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
报告专家：Zofia Piotrowska (Boston, United States of America)
LBA54：EMPOWER-Lung 1研究的3年生存结局更新&晚期NSCLC化疗进展后使用Cemiplimab（CEMI）
原标题：Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non small cell lung cancer (NSCLC): the EMPOWER-Lung 1 trial
报告专家：Mustafa Özgüroğlu (Istanbul, Turkey)
972O：O+Y 对比持续治疗6个月在晚期NSCLC的疗效：IFCT-1701 3期研究结果
原标题：Nivolumab (Nivo) plus Ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced Non-Small-Cell-Lung Cancer (aNSCLC): results of the randomized IFCT-1701 phase 3 trial
报告专家：Gerard Zalcman (Paris, CEDEX 18, France)
LBA11：IPSOS：一线阿替利珠单抗 vs 单药化疗治疗不适用铂类化疗NSCLC的3期研究
原标题：IPSOS: Results from a Phase 3 study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
报告专家：Siow Ming Lee (London, United Kingdom)
Mini Oral session
LBA55：DESTINY-Lung02 2期研究初步结果，T-DXd应用于HER2突变NSCLC
原标题：Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Mutant Metastatic Non–Small Cell Lung Cancer (NSCLC): Interim Results From the Phase 2 DESTINY-Lung02 Trial
报告专家：Koichi Goto (Kashiwa, Japan)
LBA56：MEDI5752或帕博利珠单抗联合卡铂/培美曲塞（CP）一线治疗NSCLC：一项1b/2期研究
原标题：MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): a Phase 1b/2 trial
报告专家：Myung-Ju Ahn (Seoul, Korea, Republic of)
LBA57：信迪利单抗联合安罗替尼 vs 铂类化疗，一线治疗转移性NSCLC（SUNRISE）：一项开放标签、多中心随机2期研究
原标题：Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): an open label, multi-center, randomized, phase 2 study
报告专家：韩宝惠（上海，中国）
LBA58：信迪利单抗联合或不联合 IBI305 + 化疗治疗 EGFR TKI进展的 EGFR 突变非鳞NSCLC：III期 ORIENT-31 研究第二次中期分析
原标题：Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small-cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: second interim analysis of phase 3 ORIENT-31 study
报告专家：陆舜（上海，中国）
LBA59：度伐利尤单抗±tremelimumab一线治疗转移性NSCLC，POSEIDON研究的4年随访OS更新
原标题：Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
报告专家：Melissa L. Johnson (Nashville, United States of America)
973MO：KEYNOTE-189 5年随访更新：帕博利珠单抗+培美曲塞+铂类一线治疗转移性非鳞NSCLC
原标题：KEYNOTE-189 5-year update: first-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC
报告专家：Marina C. Garassino (Chicago, United States of America)
974MO：KEYNOTE-407 5年随访更新，帕博利珠单抗与化疗在鳞状NSCLC中的对比
原标题：5-Year Update From KEYNOTE-407: Pembrolizumab Plus Chemotherapy in Squamous Non‒Small-Cell Lung Cancer (NSCLC)
报告专家：Silvia Novello (Orbassano, Italy)
LBA71：O+Y vs 化疗在不可切除的恶性胸膜间皮瘤 (uMPM) 患者中的比较：CheckMate 743的4年更新
原标题：First–line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743
报告专家：Gerard Zalcman (Paris, France)
原标题：PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: subgroup analysis of PEARLS/KEYNOTE-091
报告专家：Solange Peters (Lausanne, Switzerland)
931MO：JIPANG 3期研究最终OS分析：完全切除非鳞NSCLC中培美曲塞/顺铂 vs 长春瑞滨/顺铂
原标题：Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small-cell lung cancer: the JIPANG Study
报告专家：Kiyotaka Yoh (Kashiwa, Chiba, Japan)
929MO：度伐利尤单抗单药或联合新药在可切除、早期NSCLC中进行新辅助治疗的平台研究：NeoCOAST研究中的药效学与ctDNA动力学
原标题：Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC): pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study
报告专家：Jonathan Spicer (Montreal, Canada)
LBA50：纳武利尤单抗联合含铂双药化疗 vs 化疗，对可切除NSCLC进行新辅助治疗：来自 CheckMate 816 的健康相关生活质量 (HRQoL) 结局
原标题：Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): health-related quality of life (HRQoL) outcomes from CheckMate 816
报告专家：Enriqueta Felip (Barcelona, Spain)
1529MO：从不吸烟小细胞肺癌患者的基因组图谱
原标题：The genomic landscape of small cell lung cancer in never smoking patients
报告专家：Michael Oh (Los Angeles, United States of America)
933MO：纵向监测根治性切除的 IA-IIIA 期 EGFR 突变非小细胞肺癌患者血浆循环肿瘤 DNA
原标题：Longitudinal monitoring of circulating tumor DNA from plasma in patients with curative resected stage IA-IIIA EGFR mutant non-small cell lung cancer
报告专家：Myung-Ju Ahn (Seoul, Korea)
905MO：临床、影像学和 DNA 甲基化生物标志物的协同结合改善肺结节分类
原标题：Synergistic Combination of Clinical, Imaging and DNA Methylation Biomarkers Improves the Classification of Pulmonary Nodules
报告专家：梁文华（广州，中国）
排版编辑：肿瘤资讯-Shire
苏公网安备 32059002004080号
